Kris Meerschaert

Title: Innovations of Kris Meerschaert in Pharmaceutical Formulations

Introduction

Kris Meerschaert is a notable inventor based in Ghent, Belgium. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of FcRn inhibitors. His work focuses on creating formulations that are suitable for subcutaneous administration, which can greatly enhance the treatment options for various autoimmune diseases.

Latest Patents

Kris Meerschaert holds a patent for "Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration." This patent includes various aqueous formulations of the neonatal Fc receptor (FcRn) antagonist ARGX-113. The formulations are designed for administration to human subjects and can be used in treating conditions that benefit from the inhibition of FcRn-mediated antibody recycling. Such conditions include antibody-mediated autoimmune diseases like myasthenia gravis (MG) and immune thrombocytopenia (ITP).

Career Highlights

Kris Meerschaert is associated with Argenx Bv, a company that focuses on developing innovative therapies for severe autoimmune diseases. His work at Argenx has been pivotal in advancing the understanding and treatment of conditions that require targeted antibody therapies.

Collaborations

Kris collaborates with talented professionals in his field, including Filip Borgions and Stephanie Lemoult. Their combined expertise contributes to the innovative research and development efforts at Argenx.

Conclusion

Kris Meerschaert's contributions to pharmaceutical formulations, particularly in the area of FcRn inhibitors, highlight his role as an influential inventor in the medical field. His work not only advances scientific knowledge but also offers hope for patients suffering from autoimmune diseases.